0001638599-16-000919.txt : 20160523
0001638599-16-000919.hdr.sgml : 20160523
20160523162011
ACCESSION NUMBER: 0001638599-16-000919
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160520
FILED AS OF DATE: 20160523
DATE AS OF CHANGE: 20160523
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CorMedix Inc.
CENTRAL INDEX KEY: 0001410098
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1430 HIGHWAY 206
STREET 2: SUITE 200
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
BUSINESS PHONE: 908-517-9500
MAIL ADDRESS:
STREET 1: 1430 HIGHWAY 206
STREET 2: SUITE 200
CITY: BEDMINSTER
STATE: NJ
ZIP: 07921
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Lefkowitz Steven W
CENTRAL INDEX KEY: 0001313149
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34673
FILM NUMBER: 161669266
MAIL ADDRESS:
STREET 1: SIX HARRISON STREET
CITY: NEW YORK
STATE: NY
ZIP: 10013
4
1
doc4_3977.xml
PRIMARY DOCUMENT
X0306
4
2016-05-20
0
0001410098
CorMedix Inc.
CRMD
0001313149
Lefkowitz Steven W
C/O CORMEDIX INC.
1430 US HIGHWAY 206, SUITE 200
BEDMINSTER
NJ
07921
1
0
0
0
Common Stock, $0.001 par value per share
2016-05-20
4
S
0
14874
2.8627
D
132525
D
Common Stock, $0.001 par value per share
2016-05-23
4
M
0
50000
0.68
A
182525
D
Common Stock, $0.001 par value per share
2016-05-23
4
S
0
15126
3.00
D
167399
D
Common Stock, $0.001 par value per share
174741
I
Wade Capital Corporation Money Purchase Plan
Common Stock, $0.001 par value per share
10000
I
Reporting Person's Wife
Stock Option (right to buy)
2.02
2024-01-09
Common Stock, $0.001 par value per share
200000
200000
D
Stock Option (right to buy)
2.02
2024-01-09
Common Stock, $0.001 par value per share
30000
30000
D
Swries C-3 Non-Voting Convertible Preferred Stock
1
Common Stock, $0.001 par value per share
45000
4500
D
Warrant (right to purchase Common Stock)
0.9
2015-01-08
2020-01-08
Common Stock, $0.001 par value per share
22500
22500
D
Series C-3 Non-Voting Convertible Preferred Stock
1
Common Stock, $0.001 par value per share
30000
3000
I
Wade Capital Corporation Money Purchase Plan
Warrant (right to purchase Common Stock)
0.9
2015-01-08
2020-01-08
Common Stock, $0.001 par value per share
15000
15000
I
Wade Capital Corporation Money Purchase Plan
Stock Option (right to buy)
0.9
2023-03-20
Common Stock, $0.001 par value per share
120000
120000
D
Stock Option (right to buy)
0.68
2016-05-23
4
M
0
50000
0.00
D
2022-12-05
Common Stock, $0.001 par value per share
150000
100000
D
Stock Option (right to buy)
1.1
2021-08-11
Common Stock, $0.001 par value per share
30000
30000
D
Stock Option (right to buy)
5.62
2025-03-01
Common Stock, $0.001 par value per share
50000
50000
D
Stock Option (right to buy)
1.91
2017-09-20
Common Stock, $0.001 par value per share
75000
75000
D
The reporting person beneficially owns these securities through Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control).
The options vested 100% on January 10, 2014.
On January 8, 2014, the reporting person acquired in a private placement (i) 4,500 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of $1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock.
On January 8, 2014, the reporting person, through his ownership in Wade Capital Corporation Money Purchase Plan (an entity for which he has voting and investment control), acquired in a private placement (i) 3,000 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of $1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock.
These options vest quarterly over two years beginning June 13, 2013.
These options vested as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occuured on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.
The options vest in full on the first anniversary of the date of grant.
The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof.
Alexander M. Donalson by Power of Attorney
2016-05-23